Why Is Pharma Counterfeiting Different?
Because the victim swallows the failure: a fake lubricant seizes an engine; a fake antibiotic loses a life and triggers regulatory storm, media exposure and liability suits that reach the genuine brand. Pharma enforcement therefore runs at a different tempo, patient-safety triage first, regulator involvement early and publicity handled with extreme care.
Where Do Fakes Enter the Chain?
The recurring entry points our sweeps find:
- Sub-wholesaler layers where paperwork discipline dissolves
- Expired-stock 'recycling' (genuine packs, re-printed dates
- Look-alike branding at the retail edge) one letter off, same trade dress
- Online pharmacies and grey exporters outside authorised distribution
- Institutional supply diversions re-entering retail with forged documents
What Does an Effective Program Combine?
Layered defence: routine mystery-purchase sweeps across territories with lab authentication; distributor audits matching purchases to authorised sales; packaging security features that field teams can verify; complaint-line intelligence mined for cluster signals; and enforcement through drug control authorities, whose statutory powers make pharma raids faster and heavier than ordinary IPR actions when the evidence file arrives ready. Garuda's brand protection unit prepares exactly those files.